Low-dose memantine attenuated methadone dose in opioid-dependent patients: A 12-week double-blind randomized controlled trial

Sheng Yu Lee, Shiou Lan Chen, Yun Hsuan Chang, Po See Chen, San Yuan Huang, Nian Sheng Tzeng, Liang Jen Wang, I. Hui Lee, Tzu Yun Wang, Kao Chin Chen, Yen Kuang Yang, Jau Shyong Hong, Ru Band Lu

研究成果: Article

10 引文 斯高帕斯(Scopus)

摘要

Low-dose memantine might have anti-inflammatory and neurotrophic effects mechanistically remote from an NMDA receptor. We investigated whether add-on memantine reduced cytokine levels and benefitted patients with opioid dependence undergoing methadone maintenance therapy (MMT) in a randomized, double-blind, controlled 12-week study. Patients were randomly assigned to a group: Memantine (5 mg/day) (n = 53) or Placebo (n = 75). The methadone dose required and retention in treatment were monitored. Plasma tumor necrosis factor (TNF)-α, C-reactive protein (CRP), interleukin (IL)-6, IL-8, transforming growth factor (TGF)-β1, and brain-derived neurotrophic factor (BDNF) levels were examined during weeks 0, 1, 4, 8, and 12. General linear mixed models were used to examine therapeutic effect. After 12 weeks, Memantine-group required a somewhat lower methadone dose than did Placebo-group (P = 0.039). They also had significantly lower plasma TNF-α and significantly higher TGF-β1 levels. We provide evidence of the benefit of add-on memantine in opioid dependent patients undergoing MMT.

原文English
文章編號10140
期刊Scientific reports
5
DOIs
出版狀態Published - 2015 五月 19

All Science Journal Classification (ASJC) codes

  • General

指紋 深入研究「Low-dose memantine attenuated methadone dose in opioid-dependent patients: A 12-week double-blind randomized controlled trial」主題。共同形成了獨特的指紋。

  • 引用此